Cargando…
Preclinical Pharmacokinetics, Tissue Distribution and in vitro Metabolism of FHND6091, a Novel Oral Proteasome Inhibitor
INTRODUCTION: FHND6091, a novel N-capped dipeptidyl boronic acid proteasome inhibitor with promising pharmacological properties, entirely converted into active form FHND6081 under physiological conditions. The proteasome, a key component of the ubiquitin-proteasome pathway (UPP), has emerged as a va...
Autores principales: | Yang, Xu, Liu, Amin, Yang, Lin, Wen, Tiantian, Wang, Jia, Shi, Jingmiao, Zhou, Hui, Chen, Zhimeng, Lei, Meng, Zhu, Yongqiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482464/ https://www.ncbi.nlm.nih.gov/pubmed/36124108 http://dx.doi.org/10.2147/DDDT.S371020 |
Ejemplares similares
-
An in Vitro Assay of hERG K(+) Channel Potency for a New EGFR Inhibitor FHND004
por: Jin, Tao, et al.
Publicado: (2018) -
Complete genome sequence of Treponema succinifaciens type strain (6091(T))
por: Han, Cliff, et al.
Publicado: (2011) -
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models
por: Park, Jonghoon, et al.
Publicado: (2016) -
FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing
por: Wang, Z, et al.
Publicado: (2015) -
In vitro and in vivo efficacy of the novel oral proteasome inhibitor NNU546 in multiple myeloma
por: Zhou, Hui, et al.
Publicado: (2020)